Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 3/20 | 0.35 |
| ▸ | UGCG | Q16739 | 3/20 | 0.35 |
| ▸ | GBA2 | Q9HCG7 | 3/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | PDCD1 | Q15116 | 4/20 | 0.34 |
| ▸ | CD274 | Q9NZQ7 | 4/20 | 0.34 |
| ▸ | IDO1 | P14902 | 2/20 | 0.33 |
| ▸ | LCT | P09848 | 2/20 | 0.33 |
| ▸ | SI | P14410 | 2/20 | 0.33 |
| ▸ | MGAM | O43451 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | GCGR | P47871 | 1/20 | 0.31 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2491941 | 0.91 | CHRM3 (0.35) | GBA1UGCGGBA2CHRM3PDCD1 | |
| SCHEMBL2491327 | 0.87 | IDO1 (0.38) | GBA1UGCGGBA2IDO1PDK2 | |
| SCHEMBL2494538 | 0.84 | IDO1 (0.40) | CHRM3CD274IDO1PDK2ALDH1A1 | |
| SCHEMBL2339888 | 0.81 | IDO1 (0.50) | CHRM3IDO1ALDH1A1MAPTL3MBTL1 | |
| SCHEMBL2495686 | 0.81 | ALDH1A1 (0.34) | GBA1UGCGGBA2IDO1LCT | |
| SCHEMBL2491496 | 0.80 | SCN8A (0.36) | GBA1UGCGGBA2CHRM3PDCD1 | |
| SCHEMBL2489505 | 0.78 | HTR7 (0.38) | GBA1UGCGGBA2IDO1ALDH1A1 | |
| SCHEMBL29233791 | 0.76 | IDO1 (0.37) | CHRM3IDO1ALDH1A1MAP2K1 | |
| SCHEMBL31150411 | 0.76 | CHRM3 (0.34) | CHRM3IDO1ALDH1A1MAP2K1 | |
| SCHEMBL1005828 | 0.75 | IDO1 (0.47) | GBA1UGCGGBA2CHRM3IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3009123-A1 | MELANIN PRODUCTION INHIBITOR | Pola Chemical Industries Inc. (JP) | 2016-04-20 | — | — | EP | disclosed |
| US-20150328107-A1 | MELANIN PRODUCTION INHIBITOR | POLA CHEMICAL INDUSTRIES INC. (JP) | 2015-11-19 | — | — | US | disclosed |
| EP-2845587-A2 | Melanin production inhibitor | Pola Chemical Industries Inc. (JP) | 2015-03-11 | — | — | EP | disclosed |
| US-20140363389-A1 | MELANIN PRODUCTION INHIBITOR | POLA CHEMICAL INDUSTRIES INC. (JP) | 2014-12-11 | — | — | US | disclosed |
| US-8846012-B2 | Melanin production inhibitor | POLA CHEMICAL INDUSTRIES INC. (JP) | 2014-09-30 | — | — | US | disclosed |
| EP-2380567-A1 | MELANIN PRODUCTION INHIBITOR | Pola Chemical Industries Inc. (JP) | 2011-10-26 | — | — | EP | disclosed |
| US-20110243865-A1 | MELANIN PRODUCTION INHIBITOR | POLA CHEMICAL INDUSTRIES INC. (JP) | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110243865-A1 | MELANIN PRODUCTION INHIBITOR | TYR, F12, TH | GBA1 1822/4885UGCG 4109/4885GBA2 2834/4885 |
| US-20150328107-A1 | MELANIN PRODUCTION INHIBITOR | TYR, MC1R, F12 | GBA1 1792/4885UGCG 4111/4885GBA2 2751/4885 |
| US-20140363389-A1 | MELANIN PRODUCTION INHIBITOR | TYR, F12, MC1R | GBA1 1749/4885UGCG 4126/4885GBA2 2703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.